Cancel

Analyst consensus

Check the latest analyst estimates by VARA Research

jump to

Analyst consensus

A wide range of sell-side analysts provide coverage of dsm-firmenich for their clients and the broader market.

Sell-side analyst coverage
InstitutionAnalyst
ABN AMROStefano Toffano
Bank of America Merrill LynchMatthew Yates
BarclaysAlex Sloane
Berenberg BankSebastian Bray
BernsteinThomas Swoboda
CitigroupSebastian Satz/Ranulf Orr
Davy ResearchCathal Kenny
Deutsche BankVirginie Boucher-Ferte
EquitaMassimo Bonisoli
Exane BNP ParibasNicola Tang
Goldman SachsGeorgina Fraser
HSBCMartin Evans
INGReg Watson
JefferiesChris Counihan
JP MorganChetan Udeshi
KBC SecuritiesWim Hoste
Kepler ChevreuxMartin Rödiger
Morgan Stanley Lisa De Neve
MorningstarRob Hales
DeGroof PetercamFernand de Boer
Redburn AtlanticArtem Chubarov
StifelIsha Sharma
UBSCharles Eden
Van Lanschot Kempen Eric Wilmer

Disclaimer
Any opinions, forecasts, estimates, projections, or predictions regarding dsm-firmenich’s performance made by the analysts are theirs alone and do not represent the opinions, forecasts, estimates, projections, or predictions of dsm-firmenich or its management. By providing the names of the analysts, dsm-firmenich does not imply its endorsement of or concurrence with their reports, conclusions, or recommendations. dsm-firmenich assumes no liability for the accuracy of the information provided by analysts and undertakes no obligation to update this information.

Consensus figures per 27 November 2024

The most recent consensus figures provided by Vara Research are detailed below. The figures are based on the estimates given by the banks that were approached.

 Q4 2023H2 2023FY 2023Q3 2024Q4 2024 EH2 2024 EFY 2024 EFY 2025 E

dsm-firmenich, total sales (including temporary positive vitamin effect)

        
  - Number of Estimates    14141414
  - Highest    3,5136,75713,05514,138
  - Consensus3,1126,15812,3103,2443,2906,53412,83213,467
  - Median    3,2696,51312,81113,425
  - Lowest    3,2066,45012,74812,885
P&B, sales        
  - Number of Estimates    12121213
  - Highest    9871,9783,9854,184
  - Consensus9141,8343,7099919511,9423,9494,079
  - Median    9481,9393,9464,070
  - Lowest    9171,9083,9153,913
TTH, sales        
  - Number of Estimates    12121213
  - Highest    8291,6523,2843,490
  - Consensus7681,5053,0388237901,6133,2463,355
  - Median    7861,6093,2413,332
  - Lowest    7571,5803,2123,242
HNC, sales        
  - Number of Estimates    12121213
  - Highest    6221,1832,2742,444
  - Consensus5811,1262,2705615721,1332,2242,280
  - Median    5691,1302,2212,256
  - Lowest    5341,0952,1862,179
ANH, sales        
  - Number of Estimates    12121213
  - Highest    1,1361,9943,5304,147
  - Consensus8331,6563,2278589681,8263,3623,705
  - Median    9491,8073,3423,648
  - Lowest    8751,7333,2693,485
Corporate, sales        
  - Number of Estimates    12121213
  - Highest    24346774
  - Consensus1637661117286162
  - Median    18286163
  - Lowest    11225444
         

dsm-firmenich, total organic sales growth in % (including temporary positive vitamin effect)

        
  - Number of Estimates    12111212
  - Highest    19.013.57.89.1
  - Consensus-3.0--5.08.09.89.06.06.6
  - Median    8.68.46.06.6
  - Lowest    5.06.04.54.0
P&B, organic sales growth in %        
  - Number of Estimates    11101111
  - Highest    8.08.18.06.1
  - Consensus2.0-1.09.05.87.37.44.1
  - Median    6.07.67.44.5
  - Lowest    3.06.06.71.0
TTH, organic sales growth in %        
  - Number of Estimates    11101111
  - Highest    10.011.09.78.0
  - Consensus-1.0--1.012.06.39.18.85.6
  - Median    7.09.18.85.5
  - Lowest    2.07.67.84.0
HNC, organic sales growth in %        
  - Number of Estimates    11101111
  - Highest    10.07.61.78.0
  - Consensus4.0--4.05.03.84.50.16.5
  - Median    4.54.90.37.1
  - Lowest    -4.00.4-1.93.0
ANH, organic sales growth in %        
  - Number of Estimates    11101111
  - Highest    39.823.511.818.9
  - Consensus-12.0--13.07.018.912.87.010.6
  - Median    17.712.16.08.6
  - Lowest    6.03.04.83.0
         

dsm-firmenich, Adj. EBITDA (excluding temporary positive vitamin effect)

        
  - Number of Estimates    11111111
  - Highest    5431,0842,0602,455
  - Consensus4398481,7775415111,0522,0282,302
  - Median    5091,0502,0262,302
  - Lowest    4871,0282,0042,192
P&B, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    217443897968
  - Consensus192404783226203429883926
  - Median    202428882926
  - Lowest    192418872890
TTH, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    160322631716
  - Consensus133267556162149311620682
  - Median    147309618677
  - Lowest    140302611648
HNC, Adj. EBITDA (excluding temporary positive vitamin effect)        
  - Number of Estimates    9101010
  - Highest    119215388464
  - Consensus9416938996100196369419
  - Median    100195368419
  - Lowest    86182355389
ANH, Adj. EBITDA (excluding temporary positive vitamin effect)        
  - Number of Estimates    10101010
  - Highest    103183270446
  - Consensus32431288080160247372
  - Median    78158245369
  - Lowest    33113200294
Corporate, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    -11-34-81-44
  - Consensus-12-35-79-23-20-43-90-88
  - Median    -22-45-92-89
  - Lowest    -25-48-95-100
         

Temporary vitamin effect (positive profit impact from vitamin disruption event/ force majeure in the industry)

        
Temporary vitamin effect dsm-firmenich, adj. EBITDA        
  - Number of Estimates    11111111
  - Highest    808080300
  - Consensus----797979123
  - Median    808080100
  - Lowest    6767670
Temporary vitamin effect HNC, adj. EBITDA        
  - Number of Estimates    9101010
  - Highest    32323268
  - Consensus----66618
  - Median    00013
  - Lowest    0000
Temporary vitamin effect ANH, adj. EBITDA        
  - Number of Estimates    10101010
  - Highest    808080300
  - Consensus----737373115
  - Median    808080106
  - Lowest    4848480
         

dsm-firmenich, total Adj. EBITDA (including temporary positive vitamin effect)

        
  - Number of Estimates    14141414
  - Highest    6111,1522,1282,755
  - Consensus4398481,7775415901,1312,1072,434
  - Median    5891,1302,1062,410
  - Lowest    5671,1082,0842,264
P&B, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    217443897968
  - Consensus192404783226203429883926
  - Median    202428882926
  - Lowest    192418872890
TTH, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    160322631716
  - Consensus133267556162149311620682
  - Median    147309618677
  - Lowest    140302611648
HNC, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    130226399467
  - Consensus9416938996105201374434
  - Median    100196369431
  - Lowest    96192365402
ANH, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    168248335741
  - Consensus324312880155235322493
  - Median    158238325467
  - Lowest    113193280332
Corporate, Adj. EBITDA        
  - Number of Estimates    12121213
  - Highest    -11-34-81-44
  - Consensus-12-35-79-23-20-43-90-88
  - Median    -22-45-92-89
  - Lowest    -25-48-95-100
         
         
Core adj. EBIT  (including temporary positive vitamin effect)        
  - Number of Estimates     121313
  - Highest    -9171,4651,893
  - Consensus-391850--6831,2281,532
  - Median    -6661,1911,470
  - Lowest    -6191,1441,314
         
Core adj. net profit  (including temporary positive vitamin effect)        
  - Number of Estimates     121313
  - Highest    -6951,0601,391
  - Consensus-319555--4838641,095
  - Median    -4548261,071
  - Lowest    -396761888
         
Core adj. EPS  (including temporary positive vitamin effect)        
  - Number of Estimates     121313
  - Highest    -2.654.005.16
  - Consensus-1.162.03--1.843.244.12
  - Median    -1.733.104.04
  - Lowest    -1.492.863.35

Disclaimer
Any opinions, forecasts, estimates, projections, or predictions regarding dsm-firmenich's performance made by the analysts are theirs alone and do not represent the opinions, forecasts, estimates, projections, or predictions of dsm-firmenich or its management. By providing the names of the analysts, dsm-firmenich does not imply its endorsement of or concurrence with their reports, conclusions, or recommendations. dsm-firmenich assumes no liability for the accuracy of the information provided by analysts and undertakes no obligation to update this information.

Contact Investor relations

Whether you’re a shareholder, potential shareholder, or analyst, our Investor relations team is on hand to answer your questions.
Get in touch
Explore more
  • Executive Committee

    The Executive Committee is organized and led by our CEO, who is responsible for overseeing the operational management of the Group.

    Read more
  • Sustainability

    Sustainability is fundamental to how dsm-firmenich brings progress to life – for people and planet.

    Read more
  • Debt & credit

    dsm-firmenich bonds, other debt, credit facilities and credit ratings.

    Read more
Contact us